Disclosure of Conflict of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.
Karen Reckamp, MS, MD reported a financial interest/relationship or affiliation in the form of Consultant: Amgen, Inc; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim; Calithera Biosciences Inc; Guardant Health, Inc; Precision Therapeutics, Inc; and Takeda Oncology. Data and Safety Monitoring Board: Genentech, Inc and Tesaro, Inc. Grant/Research Support to Institution (City of Hope): AbbVie; ACEA; Adaptimmune LLC; Boehringer Ingelheim; Bristol-Myers Squibb Company; Genentech, Inc; GlaxoSmithKline; Guardant Health, Inc; Janssen Oncology; Loxo Oncology, Inc; Molecular Partners; Seattle Genetics, Inc; Spectrum Pharmaceuticals, Inc; Takeda Oncology; Xcovery; and Zenopharm.
Heather Wakelee, MD reported a financial interest/relationship or affiliation in the form of Consultant: AstraZeneca Pharmaceuticals LP; Blueprint Medicines; Daiichi-Sankyo, Inc; Helsinn Therapeutics (US) Inc; and Mirati Therapeutics. Contracted research: ACEA Biosciences; Arrys Therapeutics; AstraZeneca Pharmaceuticals LP/MedImmune; Bristol-Myers Squibb Co; Celgene Corp; Clovis Oncology; Exelixis Inc; Genentech/Roche; Lilly USA; Merck & Co Inc; Novartis Pharmaceuticals Corp; and Pfizer, Inc.
The planners, managers, and reviewers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Annette Quinn, RN, MSN; and Adrienne N. Nedved, PharmD., MPA., BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.